Philippe Horellou

Title: The Innovations of Philippe Horellou

Introduction

Philippe Horellou is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic methods for neurological disorders. His work focuses on recombinant adenoviruses and their applications in treating conditions such as Parkinson's disease.

Latest Patents

Philippe Horellou holds a patent for "Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)." This patent involves recombinant adenoviruses that comprise a heterologous DNA sequence coding for GDNF. These adenoviruses are designed to express GDNF in cells present in mammals suffering from Parkinson's disease. The method includes infecting these cells with a replication-defective recombinant adenovirus, which is administered into the central nervous system. The invention aims to provide a therapeutic effect by expressing GDNF at a level beneficial for treating Parkinson's disease.

Career Highlights

Philippe Horellou is associated with Aventis Pharma S.A., where he has been instrumental in advancing research in gene therapy and neurobiology. His innovative approaches have paved the way for new treatment methodologies that leverage the potential of recombinant adenoviruses.

Collaborations

Throughout his career, Philippe has collaborated with esteemed colleagues such as Jacques Mallet and Michel Perricaudet. These partnerships have fostered a collaborative environment that enhances research and development in the field of biotechnology.

Conclusion

Philippe Horellou's contributions to the field of biotechnology, particularly through his patent on recombinant adenoviruses, highlight his commitment to advancing medical science. His work continues to inspire innovations aimed at improving the lives of those affected by neurological disorders.